要降90%！特朗普签署行政令猛砍药价，放话不再容忍大药企、拿欧盟开刀

Core Viewpoint - President Trump is taking more aggressive actions to reduce drug prices in the U.S. by implementing a "Most Favored Nation" pricing policy, aiming to ensure that Americans pay the lowest prices for medications available globally [1][2]. Group 1: Policy Implementation - Trump signed an executive order on May 12, directing the U.S. to stop subsidizing foreign healthcare and to implement the "Most Favored Nation" pricing for drugs [1]. - The order instructs the U.S. Trade Representative and the Secretary of Commerce to take action against foreign practices that unfairly lower drug prices abroad while raising them in the U.S. [1][2]. - The Secretary of Health and Human Services is tasked with establishing a mechanism for U.S. patients to purchase drugs directly from manufacturers at the "Most Favored Nation" price, bypassing intermediaries [1]. Group 2: Expected Impact on Drug Prices - Trump indicated that some prescription drug prices could drop by 50% to 90% almost immediately as a result of this policy [2]. - The new policy is expected to significantly lower healthcare costs in the U.S., with estimates suggesting a potential decrease of 30% to 80% in drug prices [2]. Group 3: Market Reactions - Following the announcement, pharmaceutical stocks in Japan saw declines, with the pharmaceutical index dropping 3.9%, marking the largest single-day drop since August [3]. - Notable declines included Takeda Pharmaceutical Co. down 5.5% and Otsuka Holdings Co. down approximately 5.4% [3]. - In Europe, Novo Nordisk initially dropped 8.6% but later reduced its losses, closing down 0.65% [4]. Group 4: Specific Drug Categories - The executive order may include GLP-1 class drugs, such as Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Zepbound, in the price reduction scope [3].